Abstract:PURPOSE:We performed this analysis to improve the understanding of the clinicopathological characteristics and clinical outcome of non-small cell lung cancer (NSCLC) patients harboring the primary epidermal growth factor receptor (EGFR) T790M mutation along with activating EGFR mutation.METHODS:Resected tumors from 1903 NSCLC patients were analyzed for mutation in EGFR, as well as KRAS (Kirsten rat sarcoma viral oncogene homolog), BRAF (v-raf murine sarcoma viral oncogene homolog B), HER2 (human epidermal growth factor 2), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), and EML4 (echinoderm microtubule associated protein like 4)-ALK (anaplastic lymphoma receptor tyrosine kinase) fusion. Fluorescence in situ hybridization was performed to define EGFR and c-MET (met proto-oncogene gene amplification. Expression of PIK3CA and p-Akt (phosphorylated protein kinase B) were tested using immunohistochemistry. Clinical and pathological data, including sex, age at diagnosis, stage, tumor differentiation, smoking history, histological subtype, relapse-free and overall survival, were further analyzed.RESULTS:In all, 16 NSCLC patients were found to harbor primary EGFR T790M mutation, including 14 adenocarcinomas and two adenosquamous carcinomas, accounting for 2.04% of all the EGFR mutant cases and 0.84% of the total. No c-MET amplification was found to coexist with primary EGFR T790M. Fewer EGFR copy-number variations were found in samples harboring EGFR T790M mutations compared with those in patients with exon 19 deletions and L858R. Overall survival was significantly shorter for patients harboring EGFR T790M mutation than it was for patients with exon 19 deletions (logrank P=0.008). When taking patients harboring EGFR L858R or exon 19 deletions as one group, the overall survival was also significantly longer than that in patients with T790M mutation (logrank P=0.012). There was no significant difference in relapse-free survival among three subgroups of patients.CONCLUSION:Our study described the clinicopathological and molecular characteristics of NSCLC patients harboring primary EGFR T790M mutations. Its value of being a predictor for worse prognosis was established. Primary EGFR T790M mutation is a rare event in NSCLC cases, but the therapeutic strategies for this subtype of patients should be precisely considered.

The Coexistence of MET Over-Expression and an EGFR T790M Mutation is Related to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

MET Overexpression Coexisting with Epidermal Growth Factor Receptor Mutation Influence Clinical Efficacy of EGFR-tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

T790M Mutation is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients.

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR -Activating Mutation In Non- Small Cell Lung Cancer

Clinical Outcomes of EGFR+/METamp+ Vs. EGFR+/METamp‐ Untreated Patients with Advanced Non‐small Cell Lung Cancer

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Mutations in the MET Tyrosine Kinase Domain and Resistance to Tyrosine Kinase Inhibitors in Non-Small-cell Lung Cancer

Acquired Met Y1248h and D1246n Mutations Mediate Resistance to Met Inhibitors in Non-Small Cell Lung Cancer

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer after Development of EGFR-TKI Resistance

MET overexpression in EGFR L858R mutant treatment-naïve advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report

Supoemental Figure 1 Patiens Do Not Carry T790M Mutation Prior to MET-TKI Are More Likely to Have Longer PFS from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Different Characteristics and Survival in Non‐small Cell Lung Cancer Patients with Primary and Acquired EGFR T790M Mutation

Primary Concomitant EGFR T790M Mutation Predicted Worse Prognosis in Non-Small Cell Lung Cancer Patients.

Clinical outcomes of EGFR +/ MET amp + vs. EGFR +/ MET amp ‐ untreated patients with advanced non‐small cell lung cancer

Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations

Molecular features and clinical outcomes of EGFR-mutated, MET-amplified non-small-cell lung cancer after resistance to dual-targeted therapy

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer